Compare CRNX & ATMU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | ATMU |
|---|---|---|
| Founded | 2008 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.4B |
| IPO Year | 2018 | 2023 |
| Metric | CRNX | ATMU |
|---|---|---|
| Price | $84.97 | $47.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $76.75 | $58.25 |
| AVG Volume (30 Days) | ★ 2.4M | 654.5K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 0.36% |
| EPS Growth | N/A | ★ 12.61 |
| EPS | N/A | ★ 1.37 |
| Revenue | $1,039,000.00 | ★ $1,764,300,000.00 |
| Revenue This Year | $720.10 | $15.00 |
| Revenue Next Year | $184.67 | $5.13 |
| P/E Ratio | ★ N/A | $34.52 |
| Revenue Growth | N/A | ★ 5.67 |
| 52 Week Low | $32.30 | $42.60 |
| 52 Week High | $85.01 | $66.50 |
| Indicator | CRNX | ATMU |
|---|---|---|
| Relative Strength Index (RSI) | 89.88 | 44.45 |
| Support Level | $83.47 | $44.13 |
| Resistance Level | N/A | $54.95 |
| Average True Range (ATR) | 0.12 | 1.75 |
| MACD | -0.86 | -0.19 |
| Stochastic Oscillator | 93.85 | 36.38 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. It designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.